Quad-Cities Investment Group’s Teva Pharmaceuticals TEVA Stock Holding History

Quad-Cities Investment Group’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-7,027	Closed	-$49K	–	651
2019 Q3	$49K	Hold	7,027	–	–	0.04%	339
2019 Q2	$65K	Buy	7,027 +2,000	+40%	+$24.1K	0.06%	288
2019 Q1	$78K	Hold	5,027	–	–	0.07%	253
2018 Q4	$78K	Hold	5,027	–	–	0.08%	236
2018 Q3	$108K	Buy	5,027 +1,000	+25%	+$23.2K	0.1%	210
2018 Q2	$98K	Buy	+4,027	New	+$82.1K	0.09%	222

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

MVP

Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return

Quad-Cities Investment Group's TEVA Position: Q4 2019 in Review

Quad-Cities Investment Group sold out of Teva Pharmaceuticals (TEVA) in Q4 2019, closing a stake of 7,027 shares — an estimated $49K sold.

Quad-Cities Investment Group first reported a position in TEVA in Q2 2018 and held it in 6 quarters. The position peaked at $108K in Q3 2018. 436 funds tracked by Wall St. Rank hold TEVA as of Q4 2019.

Quad-Cities Investment Group reported no remaining Teva Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
Quad-Cities Investment Group sold 7,027 Teva Pharmaceuticals shares in Q4 2019, an estimated $49K.
Quad-Cities Investment Group first reported a position in Teva Pharmaceuticals in Q2 2018 and held it in 6 quarters.
Quad-Cities Investment Group's Teva Pharmaceuticals position peaked at $108K in Q3 2018.
436 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2019.

Based on Quad-Cities Investment Group's 13F filing for Q4 2019, filed 28 Jan 2020.